Latest News

Thursday, December 01, 2016 | Epilepsy & Seizure Disorders, Phase 3/4 Trials, Pfizer

Adjunctive Treatment with Lyrica Found to Reduce Seizure Frequency in Pediatric Epilepsy

New phase 3 results show that Lyrica (pregabalin, Pfizer) Capsules CV is an effective adjunctive therapy for patients with epilepsy between the ages of four and 16 years of age. Specifically, the resu…

Read the full story

Tuesday, November 29, 2016 | Movement Disorders, Research and Publications

Genetic Mutation Tied to Risk of Early Parkinson’s Disease

Aging appears to alter how genetic factors contribute to the development of Parkinson’s disease, according to new research that has identified a gene that may increase risk of early onset P…

Read the full story

Tuesday, November 22, 2016 | Dementia & Cognitive Disorders, Research and Publications

Saliva Test May Detect Alzheimer’s Disease

A new saliva test developed by Aurin Bitech could serve as a diagnostic marker for Alzheimer’s disease, according to new findings published the Journal of Alzheimers Disease. The test is based o…

Read the full story

Thursday, November 17, 2016 | Pain & Headache, Phase 3/4 Trials, Phase 3/4 Trials, Research and Publications

Investigational Biologic for the Treatment of Migraine Shows Promise in Phase 3 Data

New Phase 3 trial results suggest that Amgen’s investigational biologic agent erenumab may be effective at reducing migraines. Erenumab was specifically designed to prevent migraine by bloc…

Read the full story

Wednesday, November 16, 2016 | Healthcare Trends, Research and Publications, Visual & Sensory Disturbances

AMA Takes Policy Steps to Encourage Further CTE Research

The American Medical Association (AMA) has recently adopted new policies urging further research into the detection, causes, and prevention of head injuries. In particular, the policies encourage effo…

Read the full story

Tuesday, November 15, 2016 | FDA Approval/Clearance, Pain & Headache

New MRI Labeling Approved for St. Jude Medical’s SCS System

The FDA has approved new labeling for full-body magnetic resonance imaging (MRI) for St. Jude Medical’s Proclaim Elite Spinal Cord Stimulation (SCS) System. The new labeling ensures patients in …

Read the full story

Tuesday, November 01, 2016 | FDA Approval/Clearance, Product Launches and Updates

Portable Brain Monitoring Information System Gains FDA Clearance

A new portable ultrasound device designed for rapid triaging and monitoring of patients with brain disorders has been cleared by the FDA. The Lucid System uses Trans Cranial Doppler to non-invasively …

Read the full story

Monday, October 31, 2016 | FDA Approval/Clearance, Stroke & Cerebrovascular

PFO Occluder Approved to Reduce Risk of Recurrent Stroke

The FDA recently approved St. Jude Medical’s Amplatzer PFO Occluder to help reduce the risk of recurrent ischemic strokes in patients diagnosed with a patent foramen ovale (PFO). The Amplatzer P…

Read the full story

Friday, October 28, 2016 | Epilepsy & Seizure Disorders, Research and Publications

Phase 1 Data Show Rapid Absorption of Intranasal Midazolam in Pediatric Patients with Epilepsy

New Phase 1 data show that intranasal midazolam spray (USL261, Upsher-Smith) in pediatric participants with epilepsy is rapidly absorbed and with no dose-dependent no differences in maximum plasma con…

Read the full story

Thursday, October 27, 2016 | Neuromuscular & Immune Disorders

The Assistance Fund Now Providing Financial Assistance to Patients with Duchenne Muscular Dystrophy

The Assistance Fund, an independent charitable foundation, is opening a new fund to providing financial assistance for patients living with Duchenne muscular dystrophy. The Duchenne Muscular Dystrophy…

Read the full story

Thursday, October 27, 2016 | Dementia & Cognitive Disorders

Alzheimer’s Drug Discovery Foundation Launches Expanded Brain Health and Dementia Prevention Website

The Alzheimer’s Drug Discovery Foundation (ADDF) has relaunched, its brain health and dementia prevention website. Specifically, the site offers ratings on potential benefi…

Read the full story

Tuesday, October 25, 2016 | Dementia & Cognitive Disorders, Phase 3/4 Trials, Research and Publications

Tramiprosate Shows Gene-Dose Effect in Alzheimer’s Patients with APOE4

New phase 3 findings suggest that the investigational amyloid-targeted agent tramiprosate may particularly effective for patients with ε4 alleles of apolipoprotein E (APOE4), a genetic risk fa…

Read the full story

Monday, October 24, 2016 | Pain & Headache, Research and Publications

Oral Bacteria Linked to Migraine

Oral bacteria that convert nitrates into nitric oxide in the blood may be the key to understanding the cause of migraines, according to newly published findings. In a study published in mSystems from …

Read the full story

Wednesday, October 12, 2016 | Movement Disorders, Research and Publications

Parkinson’s Disease Therapeutic Conference to Spotlight New Research and Potential Therapeutic Targets

The Michael J. Fox Foundation’s 10th annual Parkinson’s Disease Therapeutic Conference, set to take place on October 24 in New York City, will bring together experts and specialists in res…

Read the full story

Friday, October 07, 2016 | FDA Approval/Clearance, Movement Disorders

New DBS System for Parkinson’s Disease, Essential Tremor Approved

The deep brain stimulation market will soon be expanding, as the FDA has approved St. Jude Medical’s Infinity system for the treatment Parkinson’s disease and essential tremor. Also approv…

Read the full story
Load More